SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical
company developing therapeutics for the aesthetic market, announced today that it will provide a business update and release its
first quarter 2017 financial results before the market opens on Thursday, May 11, 2017.
To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's
website at investors.neothetics.com and register for email alerts.
About Neothetics, Inc.
Neothetics is a San Diego based clinical-stage specialty pharmaceutical company developing therapeutics for the
aesthetic market. Our initial focus is on localized fat reduction and body contouring. Our lead product candidate, LIPO-202, is a
first-in-class injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate, which is an active
ingredient in the U.S. Food and Drug Administration, or FDA, approved inhaled products SEREVENT DISKUS®, ADVAIR HFA® and
ADVAIR DISKUS®. For more information on Neothetics, please visit www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are
trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of
others.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements
regarding the ability to develop a modified formulation of LIPO-202, timing of conducting and obtaining results from Phase 2
trials and proof of concept study with a modified formulation of LIPO-202, whether our modified formulation of LIPO-202 is able to
demonstrate positive results, Neothetics’ plans to research, develop and commercialize LIPO-202 and other product candidates,
our expectations regarding the potential market size and opportunity of LIPO-202, as well as expected timing for reporting results
from clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. These forward-looking statements are based
upon Neothetics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with clinical
trials, such as the ability to timely initiate clinical trials and enroll a sufficient number of patients on a timely basis into
clinical trials, the extent to which top-line data is available and whether the clinical trials achieve positive results, product
development activities, obtaining regulatory approval to commercialize LIPO-202 and other product candidates, Neothetics’ use of
cash, our ability to continue as a going concern, and the need to raise additional funding, when needed, in order to conduct our
clinical trials and other business, the degree of market acceptance of LIPO-202 by physicians, patients and others in the medical
community, our reliance on third parties, including third-party suppliers for manufacturing and distribution of products,
regulatory developments in the United States and foreign countries, Neothetics’ ability to obtain and maintain
intellectual property protection for LIPO-202 and its product candidates, competition in the aesthetics industry and other market
conditions. All forward-looking statements contained in this press release speak only as of the date on which they were
made. Neothetics undertakes no obligation to update such statements to reflect events that occur or circumstances that
exist after the date on which they were made. Investors should consult all of the information set forth herein and should also
refer to the risk factor disclosure set forth in the reports and other documents the company files with the SEC available
at www.sec.gov, including without limitation, Neothetics’ Form 10-K for the year
ended December 31, 2016 and subsequent Quarterly Reports on Form 10-Q.
COMPANY CONTACTS: Susan A. Knudson Chief Financial Officer 858-500-7780 sknudson@neothetics.com Fara Berkowitz, R.Ph, Pharm.D Senior Director, Investor Relations and Corporate Development 646-494-1589 fberkowitz@neothetics.com
